Current Report Filing (8-k)
November 05 2020 - 3:50PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 5, 2020
CORMEDIX
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State of other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
400 Connell Drive, Suite 5000
Berkeley Heights, NJ
|
|
07922
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (908) 517-9500
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2, below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
|
CRMD
|
|
NYSE American LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On
November 5, 2020, CorMedix Inc. issued a press release announcing its financial results for the third quarter ended September
30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report.
The
information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORMEDIX
INC.
|
|
|
|
Date: November 5,
2020
|
By:
|
/s/
Khoso Baluch
|
|
Name:
|
Khoso
Baluch
|
|
Title:
|
Chief
Executive Officer
|
2
false
false
0001410098
0001410098
2020-11-05
2020-11-05
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about CorMedix Inc (American Stock Exchange): 0 recent articles
More Cormedix Inc. News Articles